Kiselak Tomas
CIK 0001830177 Name as filed on the most recent filing
Filed as Kiselak Tomas (14)
17 transaction lines · from 14 filings · filed 2023-07-17 to 2026-07-20 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Crescent Biopharma, Inc. 2 filings
- ISSUER Oruka Therapeutics, Inc. 1 filings
- ISSUER Spyre Therapeutics, Inc. 1 filings
- ISSUER Zenas BioPharma, Inc. 4 filings
- ISSUER Apogee Therapeutics, Inc. 2 filings
- ISSUER Dianthus Therapeutics, Inc. /DE/ 4 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-16 |
Crescent Biopharma, Inc. CBIO |
P, Open-market purchase | 853,450 acquired | 14.50 | 12,375,025.00 | Form 4, filing 0001104659-26-085113 | |
| 2026-07-01 |
Oruka Therapeutics, Inc. ORKA |
S, Open-market sale | 3,553,410 disposed | 84.43 | 300,014,406.30 | Form 4, filing 0001104659-26-080009 | |
| 2026-06-23 |
Spyre Therapeutics, Inc. SYRE |
S, Open-market sale | 4,684,781 disposed | 85.31 | 399,658,667.11 | Form 4, filing 0001104659-26-076967 | |
| 2026-03-31 |
Zenas BioPharma, Inc. ZBIO |
P, Open-market purchase | 150,000 acquired | 20.00 | 3,000,000.00 | Form 4, filing 0001104659-26-038546 | |
| 2026-01-22 |
Apogee Therapeutics, Inc. APGE |
S, Open-market sale | 1,750,000 disposed | 76.30 | 133,525,000.00 | Form 4, filing 0001104659-26-005921 | |
| 2025-12-04 |
Crescent Biopharma, Inc. CBIO |
P, Open-market purchase | 1,360,000 acquired | 13.41 | 18,237,600.00 | Form 4, filing 0001104659-25-119320 | |
| 2025-10-07 |
Zenas BioPharma, Inc. ZBIO |
P, Open-market purchase | 316,219 acquired | 19.00 | 6,008,161.00 | Form 4, filing 0001104659-25-098362 | |
| 2024-09-16 |
Zenas BioPharma, Inc. ZBIO |
P, Open-market purchase | 300,000 acquired | 17.00 | 5,100,000.00 | Form 4, filing 0001104659-24-100766 | |
| 2024-09-16 |
Zenas BioPharma, Inc. ZBIO |
P, Open-market purchase | 300,000 acquired | 17.00 | 5,100,000.00 | Form 4, filing 0001104659-24-100330 | |
| 2023-09-29 |
Dianthus Therapeutics, Inc. /DE/ DNTH |
P, Open-market purchase | 24,670 acquired | 13.63 | 336,252.10 | Form 4, filing 0001104659-23-106378 | |
| 2023-09-26 |
Dianthus Therapeutics, Inc. /DE/ DNTH |
P, Open-market purchase | 30,000 acquired | 13.15 | 394,500.00 | Form 4, filing 0001104659-23-104808 | |
| 2023-09-19 |
Dianthus Therapeutics, Inc. /DE/ DNTH |
P, Open-market purchase | 30,000 acquired | 13.20 | 396,000.00 | Form 4, filing 0000899243-23-019370 | |
| 2023-09-13 |
Dianthus Therapeutics, Inc. /DE/ DNTH |
P, Open-market purchase | 9,367 acquired | 11.76 | 110,155.92 | Form 4, filing 0000950170-23-048022 | |
| 2023-09-12 |
Dianthus Therapeutics, Inc. /DE/ DNTH |
P, Open-market purchase | 14,887 acquired | 10.85 | 161,523.95 | Form 4, filing 0000950170-23-048022 | |
| 2023-07-13 |
Apogee Therapeutics, Inc. APGE |
P, Open-market purchase | 1,992,734 acquired | 17.00 | 33,876,478.00 | Form 4, filing 0001104659-23-081729 | |
| 2023-07-13 |
Apogee Therapeutics, Inc. APGE |
P, Open-market purchase | 892,529 acquired | 17.00 | 15,172,993.00 | Form 4, filing 0001104659-23-081729 | |
| 2023-07-13 |
Apogee Therapeutics, Inc. APGE |
P, Open-market purchase | 55,913 acquired | 17.00 | 950,521.00 | Form 4, filing 0001104659-23-081729 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Kiselak Tomas, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001830177
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6